Bafna Pharma conferred with two prestigious awards by Institute of Economic Studies

Bafna Pharmaceuticals, (BSE Code: 532989) Chennai-based pharma company engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non–Betalactum, adds another two prominent recognition to its kitty. After winning the Indian Drug Manufacturers’ Association (IDMA) Quality Excellence Awards for 2010. Bafna Pharma has been bestowed with another prestigious award. Mr. Bafna Mahaveer Chand, Chairman & Managing Director, Bafna Pharma was conferred “UDYOG RATTAN AWARD” by the Institute of Economic Studies Delhi, one of the premier research-oriented and awareness promoting global organizations and the company has been awarded the "Excellence Award". Both the awards were received by Mr. Bafna at the hands of Mr. Korn Dabbaransi, former Deputy Prime Minister of Thailand in a glittering ceremony held recently at the seminar on "Indo-Thai Economic cooperation" in Bangkok, Thailand.

Accepting the award, an elated Mr. Bafna Mahaveer Chand, Chairman and MD of Bafna Pharmaceuticals Ltd. said,” I am extremely honored to receive two prestigious awards from the Institute of Economic Studies. It is a big achievement for us as a result of our endless efforts and prolonged dedication to achieve best quality for our esteemed customers .Every award given to us is motivating us to achieve new heights”.

Institute of Economic Studies was established by a group of economists, parliamentarians and industrialists in 1980. The "Udyog Rattan Award" and the "Excellence Award" are conferred by the Institute annually and works on studying various aspects of the economy and economic development. The institute closely monitors various facets of the economy and individual contribution of various companies and business leaders.

About Bafna Pharmaceuticals Ltd:
The company has 80 products registered in UK, Sri Lanka, Ukraine, Lao, Ghana, Ethiopia, Philippians and Nigeria. The company has two manufacturing facilities. A WHO-GMP certified manufacturing facility in Madhavaram, which is a 100 percent Export oriented Unit (EOU) and an EU GMP (UK MHRA), facility at Grantlyon, Chennai. Recently, the company received Australian TGA approval and also received the Good Manufacturing Practices (GMP) approval from Ethiopia’s Drug Administration and Control Authority (DACA) for its non-betalactam facility.

The company in the month of April 2010 inaugurated its Research and Development (Formulation) (FR&D) facility, a pilot plant in Chennai. The company has secured ISO 9001: 2008 Certificate of Registration for Manufacture and Export of Pharmaceutical products. Bafna Pharma has also received EU GMP Compliances from (MHRA) Medicines and Healthcare products Regulatory Agency, U.K. This accreditation has made Bafna Pharmaceuticals the 35th facility to achieve this key recognition in India and has opened the gates for exploring markets of European Union.